Our Pricing

How to Safely Switch Mounjaro to Wegovy: UK Clinical Guidance

Many UK patients ask whether they can switch Mounjaro to Wegovy safely, and the answer is yes—under proper clinical supervision. Both medications are GLP-1 receptor agonists used for weight management, but they contain different active ingredients (tirzepatide versus semaglutide) and require careful dose conversion when transitioning. Our UK-registered clinical team provides evidence-based switching protocols to ensure continuity of treatment and minimise side effects.

Why Patients Switch Mounjaro to Wegovy in the UK

The decision to switch Mounjaro to Wegovy typically stems from three key factors: cost considerations, supply availability, or individual response to treatment. Wegovy is priced from £124.99 at Cured Pharmacy compared to Mounjaro's £124.99 starting price, making it a more economical long-term option for many patients [1]. Both medications have demonstrated significant weight loss efficacy in clinical trials, with Wegovy's STEP programme showing average weight reduction of 15-17% and Mounjaro's SURPASS trials demonstrating up to 22% reduction [2].

Some patients experience better tolerance with semaglutide (Wegovy) compared to tirzepatide (Mounjaro), particularly regarding gastrointestinal side effects. Additionally, intermittent supply issues with either medication may necessitate switching to maintain treatment continuity. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) regularly advises patients on these transitions, ensuring switches are clinically appropriate and properly managed.

Clinical Protocol to Switch Mounjaro to Wegovy Safely

The safest approach when you switch Mounjaro to Wegovy involves dose equivalence matching and appropriate timing. There is no direct milligram-to-milligram conversion between tirzepatide and semaglutide due to their different mechanisms—Mounjaro acts on both GLP-1 and GIP receptors whilst Wegovy targets GLP-1 only [3]. UK prescribers typically recommend starting Wegovy at a lower maintenance dose rather than beginning the full titration schedule from 0.25mg.

If you're currently on Mounjaro 5mg, the equivalent therapeutic effect is generally achieved with Wegovy 1.7mg. For patients on Mounjaro 10mg or 15mg, Wegovy 2.4mg (the maximum dose) is the appropriate target. The transition should occur immediately after your last Mounjaro dose—there's no need for a washout period as both medications have similar half-lives. However, your UK prescriber must approve the specific dosing protocol based on your weight loss progress, tolerance history, and clinical assessment.

Step-by-Step Switching Timeline

Week 1: Administer your final Mounjaro dose as scheduled. Week 2: Begin Wegovy at the dose equivalent recommended by your prescriber (typically 1.7mg or 2.4mg if you were on higher Mounjaro doses). Weeks 3-4: Monitor for any changes in appetite control or side effects—most patients experience seamless transition, though mild nausea may occur initially. Week 5 onwards: Continue Wegovy at your maintenance dose, with clinical review at 8-12 weeks to assess ongoing efficacy and tolerability [4].

Dose Equivalence When You Switch Mounjaro to Wegovy

Understanding dose equivalence is critical when you switch Mounjaro to Wegovy to maintain therapeutic benefit. Based on clinical experience and comparative trial data, the following conversions are recommended by UK prescribers: Mounjaro 2.5mg corresponds to Wegovy 0.5-1mg; Mounjaro 5mg to Wegovy 1.7mg; Mounjaro 7.5mg to Wegovy 2.4mg; Mounjaro 10mg and 15mg both correspond to Wegovy 2.4mg (the maximum licensed dose).

These equivalences are approximations based on weight loss outcomes rather than pharmacological potency. The STEP 1 trial showed Wegovy 2.4mg produced average weight loss of 14.9% versus placebo's 2.4%, whilst SURMOUNT-1 demonstrated Mounjaro 15mg achieved 20.9% average reduction [5]. When switching, your prescriber will consider your current weight loss trajectory, time on treatment, and individual tolerance to determine the optimal Wegovy starting dose.

Managing Side Effects During the Switch Mounjaro to Wegovy Transition

Most patients who switch Mounjaro to Wegovy experience minimal side effects during transition, particularly when appropriate dose equivalence is maintained. However, approximately 20-30% may notice temporary gastrointestinal symptoms including mild nausea, altered bowel habits, or changes in appetite intensity during the first two weeks [6]. These effects typically resolve as your body adjusts to semaglutide's receptor binding profile.

To minimise side effects when you switch Mounjaro to Wegovy, maintain consistent injection timing (same day each week), stay well-hydrated, and eat smaller, more frequent meals during the adjustment period. If you experience persistent nausea lasting beyond three weeks, contact your prescriber—they may recommend temporarily reducing your Wegovy dose before re-escalating. Serious side effects such as severe abdominal pain, persistent vomiting, or signs of pancreatitis require immediate medical attention and treatment discontinuation.

When to Contact Your Prescriber

Contact your UK prescriber if you experience any of the following after you switch Mounjaro to Wegovy: nausea preventing adequate fluid intake for more than 24 hours, severe abdominal pain radiating to the back, visual changes or signs of diabetic retinopathy progression (if diabetic), rapid heart rate or palpitations, signs of gallbladder disease including right upper quadrant pain, or unexplained weight gain suggesting treatment failure. Your prescriber can adjust dosing or recommend alternative strategies to optimise your transition.

Cost Comparison: Switch Mounjaro to Wegovy for Better Value

Financial considerations often drive the decision to switch Mounjaro to Wegovy, with potential annual savings exceeding £124.99 when choosing Wegovy. At Cured Pharmacy, Mounjaro costs from £124.99 per pen whilst Wegovy is priced from £124.99—a £20 saving per four-week treatment cycle. Over a typical 12-month weight management programme, this represents substantial cost reduction without compromising clinical outcomes.

Both medications require ongoing prescription and are not currently funded by the NHS for weight management in most Clinical Commissioning Groups, making private treatment costs a significant factor for UK patients. When you switch Mounjaro to Wegovy, you maintain access to a proven GLP-1 therapy with comparable efficacy—NICE guidance recognises both medications as effective pharmacological interventions for obesity management [7]. Cured Pharmacy offers transparent upfront pricing with no hidden consultation fees, and new patients receive £20 off their first order using code Weightlossnew.

How to Switch Mounjaro to Wegovy Through Cured Pharmacy

Switching Mounjaro to Wegovy through Cured Pharmacy involves a streamlined three-minute online consultation with our UK-registered prescribers. Complete the clinical assessment detailing your current Mounjaro dose, treatment duration, weight loss achieved, and any side effects experienced. Our prescribing team will review your suitability for Wegovy and determine the appropriate starting dose based on your Mounjaro treatment history.

Once approved, your Wegovy prescription is dispensed by our GPhC-registered pharmacy (9012511) with discreet next-day delivery across the UK. We supply only genuine UK-licensed Wegovy manufactured by Novo Nordisk, with full patient information leaflets and injection guidance. Ongoing prescriptions are managed through your patient account, with clinical reviews every 8-12 weeks to monitor progress and adjust treatment as needed. All patients receive direct access to our pharmacist team for any questions during their transition from Mounjaro to Wegovy.

What Information Your Prescriber Needs

To safely switch Mounjaro to Wegovy, your UK prescriber requires: current Mounjaro dose and duration of treatment, total weight loss achieved on Mounjaro, any side effects or tolerance issues experienced, current BMI and weight management goals, relevant medical history including diabetes status, thyroid conditions, or gastrointestinal disorders, and current medications to check for interactions. This information ensures your Wegovy prescription is clinically appropriate and dosed correctly for seamless transition [8].

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
3. Nauck, M. A., & D'Alessio, D. A. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular Diabetology, 21(1), 169. [accessed 15 August 2026]
4. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 15 August 2026]
5. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
6. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
7. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. [accessed 15 August 2026]
8. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. [accessed 15 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.